Citius Pharma in-licenses cell therapy for COVID-19 and other respiratory conditions

Novellus Therapeutics has licensed its induced mesenchymal stem cells (iMSCs) on a worldwide basis to a subsidiary of Citius Pharmaceuticals (NASDAQ:CTXR), NoveCite, Inc.
NoveCite will develop and c… [read more]

Leave a Comment